- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04576104
Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia.
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVE:
I. To compare the change in endometrial cell proliferation, as measured by the percentage (%) of Ki-67 positive cells, in participants with endometrial intraepithelial neoplasia who undergo 4 weeks of treatment with megestrol acetate + metformin or megestrol acetate alone prior to planned procedure (hysterectomy) or progestin intrauterine device [IUD] placement).
SECONDARY OBJECTIVE:
I. To measure the changes in protein expression in the endometrial intraepithelial neoplasia lesion, using immunohistochemistry (i-vi) in subjects treated with megestrol acetate + metformin compared to those treated with megestrol acetate alone.
i. Estrogen receptor (ER) and progesterone receptor (PR) ii. PTEN/PAX2 expression iii. Markers of the PI3K-Akt-mTOR pathway (phosphor-acetyl-CoA carboxylase (ACC), p(Ser473)-Akt, phosphor-S6K, p4EBP1) iv. Markers of cell death (TUNEL, cleaved caspase-3) v. Markers of intratumoral insulin signaling (Phosphorylated insulin receptor (pIR) and insulin-like growth factor-1 receptor (total and phosphorylated IGF1R), vi. Mismatch repair (MMR) deficiency (baseline only).
EXPLORATORY OBJECTIVE:
I. To explore whether baseline Ki-67 expression and other clinical characteristics are associated with treatment response.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Prior to standard of care planned procedure, patients receive megestrol acetate orally (PO) twice daily (BID) for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on the day of planned procedure.
ARM II: Prior to standard of care planned procedure, patients receive megestrol acetate PO BID and metformin hydrochloride extended-release PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy on the day of planned procedure.
After completion of study treatment, patients are followed for up to 42 days.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90048
- Active, not recruiting
- Cedars Sinai Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80217-3364
- Recruiting
- University of Colorado
-
Contact:
- Bradley R. Corr
- Phone Number: 303-724-0118
- Email: bradley.corr@cuanschutz.edu
-
Principal Investigator:
- Bradley R. Corr
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern University
-
Contact:
- Emma Barber
- Phone Number: 312-472-4684
- Email: emma.barber@northwestern.edu
-
Principal Investigator:
- Emma Barber
-
Winfield, Illinois, United States, 60190
- Recruiting
- Northwestern Medicine Central DuPage Hospital
-
Principal Investigator:
- Emma Barber
-
Contact:
- Emma Barber
- Phone Number: 312-472-4679
- Email: emma.barber@northwestern.edu
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Institute
-
Contact:
- Kevin M. Elias
- Phone Number: 617-732-8840
- Email: KELIAS@BWH.HARVARD.EDU
-
Principal Investigator:
- Kevin M. Elias
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Not yet recruiting
- University of Minnesota/Masonic Cancer Center
-
Principal Investigator:
- Britt K. Erickson
-
Contact:
- Britt K. Erickson
- Phone Number: 612-625-6716
- Email: bkeric@umn.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599
- Recruiting
- UNC Lineberger Comprehensive Cancer Center
-
Contact:
- Leslie H. Clark
- Phone Number: 919-966-5996
- Email: leslie_clark@med.unc.edu
-
Principal Investigator:
- Leslie H. Clark
-
Durham, North Carolina, United States, 27710
- Recruiting
- Duke University Medical Center
-
Contact:
- Angeles A. Secord
- Phone Number: 919-684-3765
- Email: secor002@mc.duke.edu
-
Principal Investigator:
- Angeles A. Secord
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Participants with endometrial intraepithelial neoplasia (EIN) on an endometrial biopsy or dilation and curettage specimen will be eligible. Participants diagnosed with EIN bordering on, approaching or suspicious for endometrial adenocarcinoma are allowed. Participants can be diagnosed with EIN at any time in the three months prior to enrollment. Other commonly used pathologic terms for EIN, such as complex atypical hyperplasia and atypical hyperplasia will also be eligible
- Age >= 18 years-old. EIN is almost exclusively an adult condition. Because no dosing or adverse event (AE) data are currently available on the use of megestrol acetate in participants < 18 years of age, children and adolescents are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Total bilirubin =< 1.5 x institutional upper limit of normal
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional upper limit of normal
- Creatinine =< 1.5 x institutional upper limit of normal
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients on chronic suppressive antiviral therapy for herpes simplex virus (HSV) are eligible
- If the participant is diabetic, blood glucose must be appropriately controlled as evidenced by a hemoglobin A1c of < 8.0 in the last three months prior to enrollment. If no A1c is available, it will be drawn with baseline laboratory parameters as is standard of care. For women who are diabetics who are on insulin, metformin can cause relative hypoglycemia. Women who are diabetic and receiving insulin will be allowed to participate, but will be asked to monitor their blood glucoses closely and alert the study team if persistent hypoglycemia is noted
- Must be a candidate and accepting of surgical management of EIN with planned hysterectomy or non-surgical treatment with a progestin IUD
- The effects of megestrol acetate on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, women of child-bearing potential must agree to use adequate contraception (barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately. For metformin, published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk. Metformin can increase the potential for unintended pregnancy in premenopausal women as therapy with metformin may result in ovulation in some anovulatory women
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
Current hormonal contraceptives or post-menopausal hormone replacement therapy, and uses of progestins (including progestin containing intrauterine device [IUD]) EXCEPT FOR:
- Megestrol acetate up to and including 40 mg daily
- Medroxyprogesterone acetate up to and including 10 mg daily
- Norethindrone acetate up to and including 10 mg daily
- Norethindrone up to and including 0.35 mg daily
- Oral micronized progesterone up to and including 30 0mg daily These low potency and lower dose progestins are permitted provided they have been used for less than 8 weeks (56 days) prior to enrollment and were started after the pre-treatment biopsy (e.g. endometrial biopsy or dilation and curettage). Participants will discontinue these low potency and lower dose progestins at the time of enrollment NOTES: Vaginal estrogen use is permitted. Prior use of oral contraceptives or hormonal replacement therapy is allowed, provided that it was discontinued > 3 months from current EIN diagnosis.
- Current use of selective estrogen receptor modulators (SERMs) and aromatase inhibitors. Prior use of SERMs or aromatase inhibitors is allowed, provided that it was discontinued > 3 months from current EIN diagnosis
- Current use of metformin therapy (prior use of metformin therapy is allowed, provided that it was discontinued > 1 year from trial enrollment)
- Use of GLP-1 or dual GLP-1/GIP-1 receptor agonists within 6 weeks prior to the baseline diagnostic biopsy or randomization
- Participants receiving any other investigational agents within 30 days of enrollment or during this study.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to metformin or megestrol acetate
- Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because it requires hysterectomy or progestin IUD placement which is contraindicated in women who are pregnant and wish to continue the pregnancy. Additionally, megestrol acetate is a category D agent. Megestrol acetate may cause fetal harm when administered to a pregnant woman
- Women who are breastfeeding are excluded because there is an unknown but potential risk for adverse events (AEs) in nursing infants secondary to treatment of the mother with megestrol acetate. Breastfeeding should be discontinued if the mother is treated with megestrol acetate
- Personal history of pulmonary embolism, thrombotic stroke, arterial thrombosis or deep vein thrombosis
- Women who are diabetics on insulin will be eligible to participate but they will be required to check their blood sugar regularly. Patients who are unable to check their blood sugar will be excluded from participation
- Women who are diabetics taking sulfonylureas and meglitinides will be excluded
- Women with an alcohol use or abuse disorder due to increased risk of lactic acidosis with metformin
- Current use of dofetilide, ulipristal, or carbonic anhydrase inhibitors as well as drugs that reduce metformin clearance such as ranolazine, vandetanib, dolutegravir, or cimetidine
- Cancer survivors with evidence of active disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (megestrol acetate)
Prior to standard of care planned procedure, patients receive megestrol acetate PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity.
Patients also undergo biopsy on the day of planned procedure.
|
Ancillary studies
Undergo biopsy
Other Names:
Given PO
Other Names:
|
Experimental: Arm II (megestrol acetate, metformin hydrochloride)
Prior to standard of care planned procedure, patients receive megestrol acetate PO BID and metformin hydrochloride extended-release PO BID for 21-35 days (up to and including the night before planned procedure) in the absence of disease progression or unacceptable toxicity.
Patients also undergo biopsy on the day of planned procedure.
|
Ancillary studies
Undergo biopsy
Other Names:
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Ki-67 positive cells
Time Frame: Up to 42 days post planned procedure
|
Will measure the change in endometrial cell proliferation, as measured by the percentage of Ki-67 positive cells, in subjects treated with megestrol acetate + metformin compared to those treated with megestrol acetate alone, in all evaluable participants, and following stratification by menopausal status, as well as use of low dose, low potency progestins (yes/no).
|
Up to 42 days post planned procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in protein expression
Time Frame: Baseline up to 42 days post planned procedure
|
Measured by immunohistochemistry of samples in subjects treated with megestrol acetate + metformin compared to those treated with megestrol acetate alone.
Additional analyses will be stratified for premenopausal and postmenopausal status, as well as use of low dose, low potency progestins (yes/no) to assess whether there are biologic differences in these two groups of women.
i. Estrogen receptor (ER) and progesterone receptor (PR); ii.
PTEN/PAX2 expression; iii.
Markers of the PI3K-Akt-mTOR pathway (phosphor-acetyl-CoA carboxylase (ACC), p(Ser473)-Akt, phosphor-S6K, p4EBP1);iv.
Markers of cell death (TUNEL, cleaved caspase-3);v.
Markers of intratumoral insulin signaling (Phosphorylated insulin receptor (pIR) and insulin- like growth factor-1 receptor (total and phosphorylated IGF1R); vi.
Mismatch repair (MMR) deficiency (baseline only).
|
Baseline up to 42 days post planned procedure
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ki-67 expression
Time Frame: Baseline
|
Will explore whether baseline Ki-67 expression and other clinical characteristics are associated with treatment response.
Will measure differences in the changes of Ki-67 expression of samples in subjects treated with megestrol acetate + metformin compared to those treated with megestrol acetate alone based upon the following characteristics: Baseline Ki-67 expression, ribonucleic acid sequencing analysis, and clinical characteristics (body mass index, age, etc.).
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Emma Barber, Northwestern University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Urogenital Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Neoplasms
- Carcinoma in Situ
- Hyperplasia
- Endometrial Neoplasms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Central Nervous System Stimulants
- Appetite Stimulants
- Metformin
- Megestrol
- Megestrol Acetate
Other Study ID Numbers
- NCI-2020-07529 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P30CA060553 (U.S. NIH Grant/Contract)
- UG1CA242643 (U.S. NIH Grant/Contract)
- NCI20-02-01 (Other Identifier: Northwestern University)
- NWU20-02-01 (Other Identifier: DCP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Carcinoma
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnAtypical Endometrial Hyperplasia | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IA Endometrial Carcinoma | Stage IB Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage... and other conditions
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage IVA Endometrial Carcinoma | Stage IVB Endometrial... and other conditionsCanada
-
Case Comprehensive Cancer CenterTerminatedStage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage I Endometrial CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Endometrial Adenosquamous Cell Carcinoma | Endometrial AdenoacanthomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
National Cancer Institute (NCI)NRG Oncology; Canadian Cancer Trials GroupActive, not recruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditionsUnited States, Korea, Republic of, Canada, Puerto Rico, Japan
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IV Endometrial CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingEndometrial Cancer | Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage III Endometrial Cancer | Endometrial Carcinoma Stage IIIUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Istanbul Aydın UniversityCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast Carcinoma | Fallopian Tube Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma | Deleterious CDH1 Gene Mutation | Deleterious DICER1 Gene Mutation | Deleterious SMARCA4 Gene Mutation | Deleterious STK11 Gene MutationUnited States
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation